Regenerative Medicine » Designer Children Latest News

Vomaris Innovations, Inc. Names New CEO

Feb 232012

CHANDLER, Ariz., Feb. 22, 2012 /PRNewswire/ – Vomaris Innovations, Inc., a leading regenerative medicine company focusing on wound care with bioelectric technology, has named Michael P. Nagel as its new President and Chief Executive Officer. Mr. Nagel will also join Vomaris Innovations, Inc.'s Board of Directors. Mr. Nagel brings more than 26 years of sales, marketing and management experience in the medical device industry along with a visionary leadership approach. Before joining Vomaris, Nagel served as Chief Commercial Officer of Neomend. He has also served as Vice President of Sales and Marketing at Incisive Surgical and was co-founder and Vice President of Sales and Marketing at Vascular Solutions (VASC).

At Neomend, Nagel oversaw the commercial launch of a PMA device, Progel®, a pleural air leak sealant that quickly penetrated more than 1,200 hospitals and experienced rapid sales growth in the United States and Europe. He helped take Vascular Solutions from inception to IPO in 39 months and led the launch of a novel, biological vascular closure device into the interventional marketplace. With Incisive Surgical, Nagel led the launch of a new, absorbable skin closure technology, INSORB, built the entire distribution channel, sold INSORB to more than 1,000 U.S. hospitals and then launched the technology in Europe.

“With expertise ranging from diagnostics to cardiovascular devices, Nagel's proven leadership skills in commercializing biological sealants, hemostats and biomaterials will drive the regenerative technology at Vomaris forward,” said Paul Foster, Chairman of Vomaris. “Mike brings the proven experience and leadership needed to accelerate the continued development and commercial launch of an innovative wound care technology. In addition, he brings unparalleled expertise in launching new technology into the medical marketplace that will help Vomaris expand its reach and become a global company,” continued Foster.

“I value the opportunity to work with an elite, highly focused team including employees and leading physicians who are dedicated to redefining wound care advancements,” Nagel said. “Driven by the increasing number of patients suffering from full-thickness wounds, there is a need to provide an advanced technology that will help expedite wound healing while reducing the associated pain and scarring. Vomaris is changing how wounds are managed, which will enhance the quality of patient care worldwide,” continued Nagel.

The Company's product Procellera® is the first totally self-contained, comfortable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple healthcare specialties. For more information about Procellera®, please visit www.vomaris.com.

About Vomaris Innovations, Inc.

Vomaris Innovations, Inc., based in Chandler, Arizona, is a regenerative medical device company specializing in the emerging bioelectrical field, generating innovative technologies for the wound care market. FDA cleared, Procellera® Wound Dressing is the world's first wireless, self-contained antimicrobial wound dressing that generates a sustained electrical microcurrent at its surface when activated with a conductive fluid. Procellera® is indicated for professional use for partial and full-thickness wounds such as pressure ulcers, venous ulcers, diabetic ulcers, burns, surgical incisions, and donor/recipient graft sites. Randomized controlled trials are in process to obtain clinical data for supporting expanded indications for use, including faster healing, reduced pain and decreased scarring. A recently published study in the Journal of Burn Care and Research on skin graft donor site wounds concluded that Procellera® healed wounds 35% faster and resulted in a significant decrease in scar appearance and improved patient subjective outcomes as compared to semi-occlusive control wound dressings. Vomaris' ongoing research efforts are focused on evaluating additional benefits associated with emerging bioelectrical field generating technologies. For more information, visit www.vomaris.com or call 480.921.4948.

See the original post here:
Vomaris Innovations, Inc. Names New CEO

Makucell™ Announces Key Scientific Presentations and Launch of a Large, Multicenter Use Study of Asymmtate™

Regenerative Medicine Comments Off

Feb 222012

SCOTTSDALE, Ariz., Feb. 21, 2012 /PRNewswire-USNewswire/ – Makucell, Inc., a new life science company that utilizes an innovative proprietary regenerative medicine technology to address aging skin, hair and nail conditions, has presented important pre-clinical and clinical information on its proprietary molecule, Asymmtate, at the 36th Annual Hawaii Dermatology Seminar, Waikoloa, Hawaii. Asymmtate™ is the active key ingredient in Makucell's new topical skin care line Renewnt™ (pronounced “Re-new-int”).

Asymmtate™ is a selective modulator of the Wnt (pronounced “wint”) signaling pathway that encourages optimal signaling to stimulate skin stem cells to replenish themselves, keratinocytes, fibroblasts and other dermal cells, which produce collagen, elastic tissue, matrix and other substances to foster a more healthy, rejuvenated appearing skin. Renewnt™ will be available through aesthetic dermatology professionals in April 2012.

Mark Dahl, M.D. Makucell's, Vice President and Chief Medical Officer, presented the two scientific poster presentations. The presentation titles and conclusions are summarized below.

The Safety and Efficacy of Asymmtate – Asymmtate™ penetrates into human epidermis and dermis and remains active. Asymmtate in its cream vehicles is non-mutagenic, non-irritating, and non-sensitizing. Asymmtate™ Analog Mitigates Photoaging Effects of UVB in Mice – An analog of Asymmtate applied topically can mitigate the subsequent visible appearance of photoaging changes in mice after exposures of their skin to UVB.

In addition to the pre-clinical/clinical information presented this week, Makucell has initiated a 100 subject Use Study to evaluate the safety and efficacy of Renewnt™ for Hydration Day and Night Moisturizer in a real world setting. This four-week study will include 12 investigator sites across the U.S. “This large multicenter study is very important to validate aspects of clinical product performance of Asymmtate™ under real world conditions. The diverse geographical study sites will allow us to evaluate effects on unique skin types in different climates,” said Lawrence A. Rheins, President and CEO of Makucell.

The innovative technology that resulted in the formulation of Renewnt was developed by distinguished research scientist Michael Kahn, Ph.D. and colleagues at the Eli & Edythe Broad Center for Stem Cell and Regenerative Medicine at the University of Southern California, Keck School of Medicine. “This is an exciting time for Makucell,” said Makucell co-founder and inventor Michael Kahn, Ph.D. “This technology will be utilized for commercial topical applications to address the challenges of photoaging skin and other hair and nail conditions.”

For media and investment inquiries please contact please contact Lawrence Rheins, lrheins@makucellinc.com or 1-855-MAKUCELL.

About Makucell
Makucell (www.makucell.com) is a new life science technology transfer company that utilizes an innovative proprietary regenerative medicine technology to address aging skin, hair and nail conditions in an entirely new way. Using a patent-pending new molecule, Asymmtate, Makucell has developed the Renewnt brand of non-prescription products that work with the skin's own stem cells to produce healthier, and more youthful appearing skin. This innovative technology was developed by researchers at the Eli & Edythe Broad Center for Stem Cell and Regenerative Medicine at the University of Southern California Keck School of Medicine. Makucell is financed through private investors and is not in receipt of government funding.

About the USC Stevens Institute for Innovation
The USC Stevens Institute for Innovation (http://stevens.usc.edu) is a university-wide resource in the Office of the Provost at the University of Southern California that helps identify, nurture, protect, and transfer to the market the most exciting innovations from USC. It also provides a central connection for industry seeking cutting-edge innovations in which to invest. As part of this role, the USC Stevens Institute manages the university's intellectual property portfolio stemming from its $560M annual research program. Furthermore, the USC Stevens Institute develops the innovator as well as innovations, through educational programs, community-building events, and showcase opportunities.

Media Contact:
Lawrence Rheins
lrheins@makucellinc.com
1-480-305-2061

SOURCE USC Stevens Institute for Innovation

RELATED LINKS
www.stevens.usc.edu
http://www.makucell.com/

Makucell(TM) Announces Key Scientific Presentations and Launch of a Large, Multicenter Use Study of Asymmtate(TM)

Regenerative Medicine Comments Off

Feb 222012

To: HEALTH, MEDICAL AND NATIONAL EDITORS

SCOTTSDALE, Ariz., Feb. 21, 2012 /PRNewswire-USNewswire/ — Makucell, Inc., a new life science company that utilizes an innovative proprietary regenerative medicine technology to address aging skin, hair and nail conditions, has presented important pre-clinical and clinical information on its proprietary molecule, Asymmtate, at the 36th Annual Hawaii Dermatology Seminar, Waikoloa, Hawaii. Asymmtate(TM) is the active key ingredient in Makucell's new topical skin care line Renewnt(TM) (pronounced “Re-new-int”).

Asymmtate(TM) is a selective modulator of the Wnt (pronounced “wint”) signaling pathway that encourages optimal signaling to stimulate skin stem cells to replenish themselves, keratinocytes, fibroblasts and other dermal cells, which produce collagen, elastic tissue, matrix and other substances to foster a more healthy, rejuvenated appearing skin. Renewnt(TM) will be available through aesthetic dermatology professionals in April 2012.

Mark Dahl, M.D. Makucell's, Vice President and Chief Medical Officer, presented the two scientific poster presentations. The presentation titles and conclusions are summarized below.

— The Safety and Efficacy of Asymmtate – Asymmtate(TM) penetrates into human epidermis and dermis and remains active. Asymmtate in its cream vehicles is non-mutagenic, non-irritating, and non-sensitizing. — Asymmtate(TM) Analog Mitigates Photoaging Effects of UVB in Mice – An analog of Asymmtate applied topically can mitigate the subsequent visible appearance of photoaging changes in mice after exposures of their skin to UVB.

In addition to the pre-clinical/clinical information presented this week, Makucell has initiated a 100 subject Use Study to evaluate the safety and efficacy of Renewnt(TM) for Hydration Day and Night Moisturizer in a real world setting. This four-week study will include 12 investigator sites across the U.S. “This large multicenter study is very important to validate aspects of clinical product performance of Asymmtate(TM) under real world conditions. The diverse geographical study sites will allow us to evaluate effects on unique skin types in different climates,” said Lawrence A. Rheins, President and CEO of Makucell.

For media and investment inquiries please contact please contact Lawrence Rheins, lrheins@makucellinc.com or 1-855-MAKUCELL.

About Makucell

Makucell (www.makucell.com) is a new life science technology transfer company that utilizes an innovative proprietary regenerative medicine technology to address aging skin, hair and nail conditions in an entirely new way. Using a patent-pending new molecule, Asymmtate, Makucell has developed the Renewnt brand of non-prescription products that work with the skin's own stem cells to produce healthier, and more youthful appearing skin. This innovative technology was developed by researchers at the Eli & Edythe Broad Center for Stem Cell and Regenerative Medicine at the University of Southern California Keck School of Medicine. Makucell is financed through private investors and is not in receipt of government funding.

About the USC Stevens Institute for Innovation

The USC Stevens Institute for Innovation (http://stevens.usc.edu) is a university-wide resource in the Office of the Provost at the University of Southern California that helps identify, nurture, protect, and transfer to the market the most exciting innovations from USC. It also provides a central connection for industry seeking cutting-edge innovations in which to invest. As part of this role, the USC Stevens Institute manages the university's intellectual property portfolio stemming from its $560M annual research program. Furthermore, the USC Stevens Institute develops the innovator as well as innovations, through educational programs, community-building events, and showcase opportunities.

Media Contact:

Lawrence Rheinslrheins@makucellinc.com1-480-305-2061

SOURCE USC Stevens Institute for Innovation

-0-

See more here:
Makucell(TM) Announces Key Scientific Presentations and Launch of a Large, Multicenter Use Study of Asymmtate(TM)

Celling Biosciences Sponsors 7th Annual Stem Cell Summit

Regenerative Medicine Comments Off

Feb 222012

AUSTIN, Texas, Feb. 21, 2012 /PRNewswire/ – Celling Biosciences announces a sponsorship of the 7th Annual Stem Cell Summit being held on February 21st at Bridgewaters New York in New York City. The Stem Cell Summit is consistently the premiere venue for the world's leaders in regenerative medicine to network and promote next generation technologies and cell therapies.

The meeting will feature more than 30 thought leaders in stem cell therapy including Dr. Kenneth Pettine of the Orthopedic Stem Cell Institute in Loveland, Colorado. Dr. Pettine has teamed up with Celling Biosciences' SpineSmith Division to present “Adult Stem Cell Therapy for Orthopedic and Spine Conditions Resulting from Injury or Aging.” Dr. Pettine has become an innovator in the regenerative cell therapy market and believes “regenerative therapies will become the next standard of care in treating many orthopedic conditions.”

Following the Stem Cell Summit, Dr. Pettine will be presenting a discussion on regenerative therapies to the trainers and medical staff attending this year's NFL combine. The NFL has recently gained attention from Peyton Manning going oversees to receive a cell therapy treatment for his cervical spine condition. Dr. Pettine envisions a day when these professional athletes stop going to foreign countries to receive medical treatment.

The Orthopedic Stem Cell Institute provides state-of-the-art regenerative cell therapy using Celling Biosciences' ART 21 system. The ART 21 system processes bone marrow from the patient at the point of care to consistently produce a concentrate of regenerative cells with high yields of mononuclear stem cells in less than 15 minutes. Celling Biosciences provides the cell separation systems along with the biomaterials and devices necessary to recreate the environment to promote healing.

Kevin Dunworth, founder of Celling Biosciences, believes regenerative cell therapy has more to do with creating the optimal environment then just providing cells. “We believe autologous cell therapy is a viable solution but physicians need to understand that these cells require the necessary substrate for delivery and the proper techniques for retrieval. Our focus has been on providing not only cell separation technologies, medical devices and biomaterials but also the registered nurses to deliver the service so physicians can have the most consistent, reliable and predictable regenerative cell therapy for their patients.”

Contact:
Tracy Gladden
Communications Manager
Tgladden@spinesmithusa.com
512-637-2050

About Celling Biosciences
Celling Biosciences, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the field of regenerative medicine. www.cellingbiosciences.com and www.spinesmithusa.com

Continued here:
Celling Biosciences Sponsors 7th Annual Stem Cell Summit

Regenerative medicine mujaddidon's project.wmv - Video

Regenerative Medicine Comments Off

Feb 212012

01-01-2012 13:40

See the rest here:
Regenerative medicine mujaddidon’s project.wmv – Video

Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview

Regenerative Medicine Comments Off

Feb 202012

NEW YORK, Feb. 20, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Tissue Engineering: The Combination of Cells & Engineering – A Global Market Overview

http://www.reportlinker.com/p0774604/Tissue-Engineering-The-Combination-of-Cells–Engineering—A-Global-Market-Overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Advancements of novel therapies in the fields of tissue engineering and regenerative medicine have opened up new avenues for addressing a range of major diseases such as cancer; skin; cardiovascular conditions; urology; dental; neurological disorders including Alzheimer's and Parkinson's; and other. Engineered tissues can be successfully constructed through the recreation of a biologically active extracellular environment in which the product can be developed. These technologies offer new hope for medical progress, and the economies of emerging nations have recognized the potential of tapping into these fast emerging fields to gain maximum mileage.

The global market for the therapeutic areas of Tissue Engineering analyzed in this study comprises Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other. Individual regions analyzed in the study includes the United States, Europe, Asia-Pacific and Rest of World. Estimated to value US$11 billion in 2012, the global market for tissue engineering is expected to touch US$27 billion by 2018.

This 153 page global market report includes 27 rich data tables, supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the global market value by geographic regions and application areas.

The report covers the brief business profiles of 60 major players across the United States – 47; Europe – 10; Asia-Pacific – 2; and Rest of World – 1. The report also provides the listing of the companies engaged in the business related to Tissue Engineering. The global list covers the addresses, contact numbers and the website addresses of 364 companies.

TABLE OF CONTENTS:1. INTRODUCTION2. PRODUCT OUTLINE2.1 Biomaterials

2.2 Cells

2.3 Biomolecules

2.4 Aspects of Engineering Design

2.5 Biomechanical Design Aspects

2.6 Informatics to Support Tissue Engineering

2.7 Stem Cell Research

2.8 Therapeutic Applications of Tissue Engineering and Regenerative Medicine

2.8.1 Orthopedic Applications

2.8.1.1 Bone Regeneration Using Orthopedic Tissue Engineering

2.8.1.2 Articular Cartilage Degeneration and Osteoarthritis, Repair, Regeneration and Transplantation

2.8.1.2.1 Cartilage Repair

2.8.1.2.2 Osteochondral Allograft Transplantation

2.8.2 Skin/Integumentary Applications

2.8.2.1 Burns

2.8.2.2 Diabetic Ulcers

2.8.2.3 Venous Ulcers

2.8.2.4 Plastic and Reconstructive Surgery

2.8.3 Oncology Applications

2.8.3.1 Cancer

2.8.3.2 Cancer Biology from Tissue Engineering's Perspective

2.8.3.3 Tissue Engineering Technology Platforms' Translation into Cancer Research

2.8.4 Cardiovascular Applications

2.8.4.1 Cardiac Tissue Engineering: An Overview

2.8.4.2 Identification of Basic Cell Responses

2.8.4.2.1 Materials and Degradation

2.8.4.2.2 Attachment

2.8.4.2.3 Stiffness

2.8.4.2.4 Diffusion and Porosity

2.8.4.2.5 Forces

2.8.4.3 3-Dimensional Tissue Engineering

2.8.4.4 Further 3-D Approaches and Considerations

2.8.4.5 Cardiovascular Tissue Engineering and Bioreactor Technology

2.8.4.6 Limiting Cells or Materials

2.8.5 Dental

2.8.5.1 Dental Tissue Regeneration through Tissue Engineering Strategy

2.8.5.2 Harvesting Teeth Created by Tissue Engineering

2.8.5.3 Research Goals Currently Targeted

2.8.5.4 Process of Tissue Engineering for Tooth Replacement: What Future Trends Indicate

2.8.6 Neurology Applications

2.8.6.1 Neural Tissue Engineering or Neuroregeneration

2.8.6.2 Biomaterial Scaffold Development for Nerve Tissue Engineering: Biomaterial Mediated Neural Regeneration

2.8.6.2.1 Response to Injury and Repair

2.8.6.2.2 Neural Cells' Regeneration Potential

2.8.6.2.3 Regeneration Promoted through Growth Factor Delivery

2.8.6.2.4 Biomaterials in Nerve Regeneration

2.8.6.2.5 Polymeric Scaffolds as Extracellular Matrix Analogues

2.8.6.2.6 Geometric Indicators: Structure of Scaffolds

2.8.6.2.7 Nanofiber Properties and Electrospinning Technology

2.8.6.2.8 Alternate Approaches

2.8.6.2.9 Electrical Cues

2.8.7 Urological Applications

2.8.7.1 Conditions Affecting the Urological System

2.8.7.1.1 The Kidney

2.8.7.1.2 The Ureter

2.8.7.1.3 The Urinary Bladder

2.8.7.1.4 The Urinary Sphincters

2.8.7.1.5 The Urethra

2.8.7.2 Stem Cells Offering Promise in Urological Regenerative Medicine

2.8.7.3 Polymeric Materials and their Potential Applications in Urologic Regenerative Medicine

2.8.8 Organ Transplantation

2.8.8.1 Categories of Transplant

2.8.8.2 Major Organs and Tissues Transplanted

3. KEY MARKET TRENDSWhat Lies in Store for Cartilage Regeneration Stem Cells

Improved Scaffold for Bone Tissue Engineering Developed by Iranian Researchers

Magnetic Levitation for Bio-Assembling in 3-D

UK's Footing in Regenerative Medicine Gaining Pace

Chondrogenesis and Cartilage Tissue Engineering: The Way Ahead

Regenerative Medicine Evolving, though Investors Still Wary

Scientific Innovation Announced by LifeNet Health's Institute of Regenerative Medicine

Skin Stem Cells to Cure Genetic Liver Disease

Future Markets for Tissue Engineering and Cell Therapy

Timescale for Development

Tissue Engineering and Ultrasound Technologies

Overview of Myocardial Tissue Engineering (MTE)

Future of Bone Regeneration and Organ Printing

New Tissue Engineering Technology on the Way for Patients with Osteoarthritis

Leg Muscle Regenerated from Pig Bladder Cells

Loading Device for Intervertebral Disc Tissue Engineering

Rodent Spine Biomechanical Function Restored with Tissue-Engineered Intervertebral Discs

Engineering Human Tissue Regeneration via Novel Method

Heart Tissue Healing Assisted by New Nanotechnology

Developing Bioengineered Veins with Tissue Engineered Vascular Grafts a Promising Prospect

New Organs, New Hope for Children Offered by Regenerative Medicine

TERM: A Consortium Formed by Eight European Regions to Focus on Bolstering Tissue Engineering and Regenerative Medicine Initiatives

An Overview of Dental Pulp Tissue Engineering

Bioactive Electrospun Scaffolds to Deliver Growth Factors and Genes for Tissue Engineering Applications

Regenerative Medicine: Progress and Prospects

“Bio-Legos”: An Innovation in Tissue Engineering

Pioneering Tissue-Engineered Urethras Report Success

4. MAJOR MARKET PLAYERSAdvanced Cell Technology Inc

Aesculap/B. Braun

Athersys Inc

Baxter International Inc

Bayer Healthcare Pharmaceuticals

Biocomposites Ltd

Biolife Solutions Inc

Biomet Inc

Biotissue Technologies GmbH

Cardium Therapeutics

Celgene Corporation

Cellerant Therapeutics Inc

Corcell Companies, Inc

Cryobanks International Inc

Cryo-Cell International, Inc

Cryolife, Inc

Cryo-Save Group N.V.

Cytori Therapeutics Inc

Depuy

Eli Lilly and Co

ES Cell International Pte Ltd

Gamida Cell Ltd

Genta, Inc

Genzyme Biosurgery Corp

Genzyme Corp

Geron Corporation

Glaxosmithkline Plc

Histogenics Corp

Incytu Inc

Integra Lifesciences Inc

International Stem Cell Corporation

Johnson & Johnson Inc

Kensey Nash

Kinetic Concepts, Inc.

Lifecell Corp

Lifecord International Co Ltd

Medtronic Sofamor Danek Inc

Neostem, Inc.

Novartis Ag

Novo Nordisk A/S

Organogenesis Inc.

OSI Pharmaceuticals Inc

Osiris Therapeutics Inc.

Osteotech, Inc.

Pfizer Inc

Regenerative Sciences Institute

RTI Biologics, Inc

Sanofi-Aventis

Smith & Nephew Ltd

Stryker Corporation

Synovis Life Technologies, Inc

Synovis Orthopedic and Woundcare, Inc

Tengion, Inc

Thermogenesis Corp

Tissue Engineering, Inc.

Tissue Repair Company

Viacord

Viacyte, Inc.

W.L. Gore & Associates

Zimmer Holdings Inc

5. KEY BUSINESS TRENDSNeoStem Completes Amorcyte Acquisition

British Stem Cell Center Given the Go Ahead

Aragon Surgical, Inc Taken Over by Aesculap

Cellectis Acquires Cellartis

Advanced BioHealing, Inc Acquired by Shire plc

ProChon BioTech Acquired by Histogenics

Integra LifeSciences Takes Over SeaSpine

Stryker Acquires Orthovita

Medtronic's Minority Stake in Tengion with a Focus on Regenerative Medicine Market

Cardiogenesis Acquired by CryoLife

Trial for Stem Cell-Based Therapy for IBD Commenced by Athersys-Pfizer

BioTime Acquires Glycosan BioSystems

Two Innovative Technologies Acquired by Boston Scientific

Allograft Cancellous Sponge Introduced by Integra LifeSciences

Eli Lilly in Partnership with the Juvenile Diabetes Research Foundation

Cell Targeting, Inc Acquired by BioTime

Boston Scientific Acquires Atritech

Intelect Medical Taken Over by Boston Scientific

Progenitor Cell Therapy Taken Over by NeoStem

Avid Radiopharmaceuticals Taken Over by Eli Lilly

Integra™ Endoscopic Gastroc Release System (EGR) Launched by Integra LifeSciences

Integra LifeSciences Launches New Range of Surgical Spine Instruments

Lilly Acquires Alnara Pharmaceuticals

Celgene Acquires Abraxis BioScience Inc

First Regenerative Medicine Product from Harvard Bioscience

Novel Bioactive Scaffold from Drexel

6. GLOBAL MARKET OVERVIEW6.1 Global Market Analysis by Therapeutic Area

Chart 1: Global Tissue Engineering Market Analysis (2008-2018) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other in USD Million

Chart 2: Glance at 2008, 2013 and 2018 Global Tissue Engineering Market Share (%) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other

6.2 Tissue Engineering Therapeutic Area Analysis by Global Region6.2.1 Orthopedics

Chart 3: Global Market Analysis of Tissue Engineering in Orthopedic Applications (2008-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 4: Glance at 2008, 2013 and 2018 Global Market Share (%) of Tissue Engineering in Orthopedic Applications by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

6.2.2 IntegumentaryChart 5: Global Market Analysis of Tissue Engineering in Integumentary Applications (2008-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 6: Glance at 2008, 2013 and 2018 Global Market Share (%) of Tissue Engineering in Integumentary Applications by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

6.2.3 Oncology

Chart 7: Global Market Analysis of Tissue Engineering in Oncology Applications (2008-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 8: Glance at 2008, 2013 and 2018 Global Market Share (%) of Tissue Engineering in Oncology Applications by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

6.2.4 CardiologyChart 9: Global Market Analysis of Tissue Engineering in Cardiology Applications (2008-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 10: Glance at 2008, 2013 and 2018 Global Market Share (%) of Tissue Engineering in Cardiology Applications by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

6.2.5 Dental

Chart 11: Global Market Analysis of Tissue Engineering in Dental Applications (2008-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 12: Glance at 2008, 2013 and 2018 Global Market Share (%) of Tissue Engineering in Dental Applications by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

6.2.6 NeurologyChart 13: Global Market Analysis of Tissue Engineering in Neurology Applications (2008-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 14: Glance at 2008, 2013 and 2018 Global Market Share (%) of Tissue Engineering in Neurology Applications by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

6.2.7 Other Therapeutic Areas

Chart 15: Global Market Analysis of Tissue Engineering in Other Therapeutic Applications (2008-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 16: Glance at 2008, 2013 and 2018 Global Market Share (%) of Tissue Engineering in Other Therapeutic Applications by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

7. REGIONAL MARKET OVERVIEWChart 17: The Projection of Key Market Region in terms of Growth for Tissue Engineering by Geography – Asia-Pacific, South America, Europe and North America

Chart 18: Global Tissue Engineering Market Analysis (2008-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 19: Glance at 2008, 2013 and 2018 Global Tissue Engineering Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

7.1 THE UNITED STATESChart 20: United States Tissue Engineering Market Analysis (2008-2018) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other in USD MillionChart 21: Glance at 2008, 2013 and 2018 United States Tissue Engineering Market Share (%) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other

7.2 EUROPE

Chart 22: Western Europe Tissue Engineering Market Analysis (2008-2018) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other in USD Million

Chart 23: Glance at 2008, 2013 and 2018 Western Europe Tissue Engineering Market Share (%) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other

7.3 ASIA-PACIFICChart 24: Asia-Pacific Tissue Engineering Market Analysis (2008-2018) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other in USD MillionChart 25: Glance at 2008, 2013 and 2018 Asia-Pacific Tissue Engineering Market Share (%) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other

7.4 REST OF WORLD

Chart 26: Rest of World Tissue Engineering Market Analysis (2008-2018) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other in USD Million

Chart 27: Glance at 2008, 2013 and 2018 Rest of World Tissue Engineering Market Share (%) by Therapeutic Area – Orthopedics, Integumentary, Oncology, Cardiology, Dental, Neurology and Other

8. GUIDE TO THE INDUSTRY8.1 North America

8.1.1 Canada

8.1.2 United States

8.2 Europe8.2.1 Belgium8.2.2 Cyprus8.2.3 Denmark8.2.4 Finland8.2.5 France8.2.6 Germany8.2.7 Iceland8.2.8 Ireland8.2.9 Italy8.2.10 Luxembourg8.2.11 Spain8.2.12 Sweden8.2.13 Switzerland8.2.14 The Netherlands8.2.15 Turkey8.2.16 United Kingdom

8.3 Asia-Pacific

8.3.1 Australia

8.3.2 China

8.3.3 Hong Kong

8.3.4 India

8.3.5 Japan

8.3.6 Malaysia

8.3.7 New Zealand

8.3.8 Singapore

8.3.9 South Korea

8.4 Rest of World8.4.1 Argentina8.4.2 Israel9. ANNEXURE9.1 Research Methodology9.2 The Questionnaire9.3 FeedbackTo order this report: Biological Therapy Industry: Tissue Engineering: The Combination of Cells & Engineering – A Global Market Overview

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

See the rest here:
Tissue Engineering: The Combination of Cells & Engineering – A Global Market Overview

BioTime CEO Michael D. West to Present at New York Stem Cell Summit

Regenerative Medicine Comments Off

Feb 172012

ALAMEDA, Calif.–(BUSINESS WIRE)–

BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 7th Annual New York Stem Cell Summit at Bridgewaters New York City on Tuesday, February 21, 2012 at 8:48 a.m. ET. Dr. West will provide an update and new information on the Company's manufacturing technologies and cell-based therapeutics in development. The presentation will be available online at www.biotimeinc.com.

The annual New York Stem Cell Summit provides investors, industry, practitioners, and analysts with the latest developments and investment opportunities in the stem cell marketplace.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate™ cell lines, culture media, and differentiation kits. BioTime's wholly owned subsidiary ES Cell International Pte. Ltd. has produced clinical-grade human embryonic stem cell lines that were derived following principles of Good Manufacturing Practice and currently offers them for use in research. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. Cell Cure's minority shareholder Teva Pharmaceutical Industries has an option to clinically develop and commercialize Cell Cure's OpRegen™ retinal cell product for use in the treatment of age-related macular degeneration. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-DxTM currently being developed for the detection of cancer in blood samples, therapeutic strategies using vascular progenitor cells engineered to destroy malignant tumors. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's newest subsidiary, LifeMap Sciences, Inc., is developing an online database of the complex cell lineages arising from stem cells to guide basic research and to market BioTime's research products. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low-temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, ReCyte Therapeutics, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, LifeMap Sciences, and ESI can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:
http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Excerpt from:
BioTime CEO Michael D. West to Present at New York Stem Cell Summit

Histogenics to Present at 7th Annual New York Stem Cell Summit

Regenerative Medicine Comments Off

Feb 172012

WALTHAM, Mass.–(BUSINESS WIRE)–

Histogenics Corporation, a privately held regenerative medicine company, today announced that the Company will present at the 7th Annual New York Stem Cell Summit on February 21st at Bridgewaters New York City. Kirk Andriano, Ph.D., Vice President of Research and Development for Histogenics, will speak about current and future cell therapies being developed by the Company as it works toward commercialization. Lead candidates include NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix designed to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met and a favorable safety profile was demonstrated.

Dr. Andriano earned his BS in chemistry and biology from Utah State University and his MS and Ph.D. in bioengineering from the University of Utah. Prior to his work at Histogenics, he was the Chief Technology Officer for ProChon Biotech, Ltd. which was acquired by Histogenics in May 2011.

About Histogenics

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopaedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials of its NeoCart autologous tissue implant and is currently in a Phase 3 IND clinical study. Based in Waltham, Massachusetts, the company is privately held. For more information, visit www.histogenics.com.

See original here:
Histogenics to Present at 7th Annual New York Stem Cell Summit

Biomask: Improving Facial Burn Treatment for Soldiers in the Field

Regenerative Medicine Comments Off

Feb 172012

Current treatments for facial injuries often lead to disfigurement or speech impediments, but the Biomask could change regenerative medicine.

It's estimated that 85 percent of injuries to our armed forces in the field cause damage to the extremities or the face. Innovations in regenerative medicine are moving along at an amazing pace, but the common current facial burns treatment typically involves removing damaged areas, followed by skin grafting, which usually leads to disfigurement and the possibility of speech impediments and scarring.

A new project called Biomask, a collaboration between engineers at the University of Texas, Arlington; Northwestern University regenerative medicine specialists; leaders in burn treatment at Brooke Army Medical Center; and consultants Army Institute of Surgical Research seeks to improve burn treatment outcomes with the latest in medical electronics and regenerative medicine.

The Biomask consists of two layers: The top layer is a hard shell that protects the wearer's face and stores the electronic components. The second layer is a polymer mask that will fit around the contours of the face. The polymer also acts as a seal around the wounds which compresses them to prevent lumpy scar formation. The polymer shell is also embedded with a number of sensors and actuators to monitor the healing process and send data to physicians.

While the mask itself will already improve treatment outcomes, Biomask takes it a step further by featuring a network of microtubes and valves in the polymer layer that will constantly deliver therapeutics, such as painkillers, antibiotics, and stem cells to the parts of the face that the onboard sensors determine.

Altogether, this makes Biomask a highly customized and automated 24/7 treatment system that researchers hope will make healing faster and better.

This post also appears on medGadget, an Atlantic partner site.

Originally posted here:
Biomask: Improving Facial Burn Treatment for Soldiers in the Field

Provia Labs Makes Chicago Midwinter Meeting Debut and Launches Store-A-Tooth™ Dental Stem Cell Preservation, Enabling ...

Regenerative Medicine Comments Off

Feb 162012

Dentists can be at the forefront of the emerging field of regenerative medicine by offering Store-A-Tooth™ dental stem cell banking.

This service enables families to save their own adult stem cells from teeth that are naturally coming out or being extracted. Dental professionals play a role in making patients aware of this option, giving families the choice to safely and securely store their stem cells today – in a convenient and affordable way – so that they can take advantage of future therapies in regenerative medicine and dentistry.

Provia Laboratories, LLC will be exhibiting its Store-A-Tooth™ dental stem cell preservation service during the Chicago Midwinter Meeting at booth # 3346.

Lexington, MA (PRWEB) February 15, 2012

Provia Laboratories, LLC will be exhibiting during the Chicago Midwinter Meeting at booth # 3346 to showcase its Store-A-Tooth™ dental stem cell preservation service.

The Store-A-Tooth service enables families to save their own adult stem cells – from baby teeth ready to fall out; teeth pulled for orthodontic reasons; and wisdom teeth being extracted. Dental professionals play a role in making patients aware of this option, giving families the choice to safely and securely store their stem cells today – in a convenient and affordable way – so that they can take advantage of future therapies in regenerative medicine and dentistry.

The company partners with dental offices to make it easy to educate and inform patients about the option to preserve their family’s dental stem cells. For those interested in the service, Provia works with the dental team to provide high quality tooth collection, and arranges for the sample to be sent overnight to the lab, where the stem cells are harvested, tested and cryopreserved for future potential use.

“New stem cell therapies are going to change medicine as we know it, and dentists will play a leading role in enabling this transformation,” states Howard Greenman, Provia Labs CEO. “There’s been a lot of media buzz about stem cell research in general, but most people are unaware that a very potent and plentiful source of viable stem cells exists in the dental pulp of healthy teeth.”

Dental stem cells have already successfully been used in people to regenerate alveolar jaw bone and to treat periodontal disease. “One of the first routine applications in the oral cavity for the use of mesenchymal stem cells from teeth will be to promote bone growth around implants so they integrate more quickly, similar to how cellular bone matrix products are used today,” says Dr. Nicholas Perrotta, DMD, who started providing the Store-A-Tooth service in 2011.

“In addition to potential applications in regenerative dentistry, dental stem cell research may lead to new treatments for a wide range of medical conditions, including type 1 diabetes, stroke, cardiovascular disease, spinal cord injuries, and Parkinson’s disease, to name a few,” explains Peter Verlander, PhD, Chief Scientific Officer for Provia Labs. “Dental stem cell collection and preservation gives parents the peace of mind that they are now equipped to take advantage of the breakthroughs in stem cell therapies that will arise from the research community.”

“Store-A-Tooth is less expensive than collecting stem cells from umbilical cord blood. In fact, we hear from many of our customers that they are thankful to have this opportunity to store their stem cells, especially if they missed the chance to save cord blood,” states Greenman. “Our mission is to make stem cell banking accessible to the millions of children losing teeth every year.”

There are no fees or costs to dentists who wish to become an authorized Store-A-Tooth provider; in fact dentists can generate incremental revenue for assisting with tooth collection. Provia Labs supplies all participating practices with patient education materials, practice tools and dedicated support; training is simple and there is minimal impact to existing workflow.

Dental professionals share Store-A-Tooth educational materials with their patients, who enroll directly with Provia Labs. The day of the appointment, the dentist simply places the extracted tooth into the Store-A-Tooth collection kit, which includes a proven transport device called Save-A-Tooth®. In use by thousands of dentists for over 20 years, the Save-A-Tooth is an FDA-approved and ADA-accepted device for transporting avulsed teeth for reimplantation. The Store-A-Tooth collection kit is shipped overnight to the Provia Laboratories facility, where the stem cells are processed and stored.

The Store-A-Tooth service is currently available to dental offices throughout the United States and internationally. To become a provider, visit http://www.store-a-tooth.com or call 877-867-5753.

About Provia Laboratories, LLC

Headquartered in Lexington, MA, Provia Laboratories, LLC (http://www.provialabs.com) is a healthcare services company specializing in high quality biobanking (preservation of biological specimens). The company’s Store-A-Tooth™ service platform enables the collection, transport, processing, and storage of dental stem cells for potential use in future stem-cell therapies. The company advises industrial, academic, and governmental clients on matters related to the preservation of biological specimens for research and clinical use. In addition, Provia offers a variety of products for use in complex biobanking environments to improve sample logistics, security, and quality. For more information on dental stem cells, call 1-877-867-5753, visit http://www.store-a-tooth.com or http://www.facebook.com/storeatooth, or follow via twitter @StoreATooth.

###

Store-A-Tooth
Provia Laboratories, LLC
877-867-5753
Email Information

Here is the original post:
Provia Labs Makes Chicago Midwinter Meeting Debut and Launches Store-A-Tooth™ Dental Stem Cell Preservation, Enabling …

Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for ...

Regenerative Medicine Comments Off

Feb 162012

MARLBOROUGH, Mass.–(BUSINESS WIRE)–

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the company’s Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD), a form of juvenile macular degeneration, using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. Earlier this year, the Company also announced that the IRB at Wills Eye Institute had approved the participation of the institution as a site for ACT’s clinical trial for dry age-related macular degeneration (dry AMD).

“We thank Wills Eye Institute once more for providing their IRB and their invaluable contribution to our macular degeneration studies,” said Gary Rabin, ACT’s chairman and CEO. “We are very happy that we can now report that Wills Eye Institute has been approved as a clinical trial site for both our SMD and dry AMD clinical trials. Ranked as one of the best ophthalmology hospitals in the country by U.S. News & World Report, the Wills Eye Institute is a truly world-class institution. Our team is eagerly anticipating working with Dr. Carl Regillo, a renowned retinal surgeon and director of clinical retina research at Wills Eye Institute, as well as a professor of ophthalmology at Thomas Jefferson University, along with the rest of his team as we move forward with these ground-breaking trials.”

The Phase I/II trial for SMD is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with SMD. The trial will ultimately enroll 12 patients, with cohorts of three patients each in an ascending dosage format. Preliminary results relating to both early safety and biological function for the first two patients in the U.S., one SMD patient and one dry AMD patient, were recently reported in The Lancet.

Specific patient enrollment for both trials at the Wills Eye Institute will be determined in the near future. Further information about patient eligibility for the SMD study and the concurrent study on dry AMD is also available on www.clinicaltrials.gov; ClinicalTrials.gov Identifiers: NCT01345006 and NCT01344993.

About Stargardt's Disease

Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium.

About hESC-derived RPE Cells

The retinal pigment epithelium (RPE) is a highly specialized tissue located between the choroids and the neural retina. RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors. Human embryonic stem cells differentiate into any cell type, including RPE cells, and have a similar expression of RPE-specific genes compared to human RPE cells and demonstrate the full transition from the hESC state.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.

About Wills Eye Institute

Wills Eye Institute is a global leader in ophthalmology, established in 1832 as the nation’s first hospital specializing in eye care. U.S. News & World Report has consistently ranked Wills Eye as one of America’s top three ophthalmology centers since the survey began in 1990. Wills Eye is a premier training site for all levels of medical education. Its resident and post-graduate training programs are among the most competitive in the country. One of the core strengths of Wills is the close connection between innovative research and advanced patient care. Wills provides the full range of primary and subspecialty eye care for improving and preserving sight, including cataract, cornea, retina, emergency care, glaucoma, neuro-ophthalmology, ocular oncology, oculoplastics, pathology, pediatric ophthalmology and ocular genetics, refractive surgery and retina. Ocular Services include the Wills Laser Correction Center, Low Vision Service, and Diagnostic Center. Its 24/7 Emergency Service is the only one of its kind in the region. Wills Eye also has a network of nine multi-specialty, ambulatory surgery centers throughout the tri-state area. To learn more, please visit www.willseye.org.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.

Cytomedix to Showcase Aldagen's Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings

Regenerative Medicine Comments Off

Feb 162012

GAITHERSBURG, MD–(Marketwire -02/16/12)- Cytomedix, Inc. (OTC.BB: CMXI.OB – News) (the “Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that Chief Operating Officer Edward L. Field will present a clinical overview of Aldagen's autologous cell therapy technology at two upcoming meetings: The Cell Society's 2nd Annual Clinical Meeting being held February 17-18 at the Coronado Marriott Resort in San Diego; and the 7th Annual New York Stem Cell Summit being held on February 21 at Bridgewaters New York in New York City.

Mr. Field will present during the session, “Commercialization Opportunities with Adult Stem Cell Therapies,” on Friday, February 17 from 8:00 a.m. to 10:00 a.m. Pacific time at the Cell Society meeting.

Cell Society International is a non-profit organization dedicated to advancing the clinical application of adult stem cell therapies worldwide. Cell Society's 2nd Annual Clinical Meeting will continue in the tradition established at the 1st Annual Meeting and will offer a unique opportunity for multidisciplinary, international clinical collaboration designed to enhance understanding and thought-provoking insight into treatments and cures for disease and agonizing medical conditions. This year's clinical focus will center on therapies particularly relevant to cardiology, neurology, and orthopedic and plastic surgery.

At the Stem Cell Summit, Mr. Field will present at 2:35 p.m. Eastern time. This meeting showcases more than 30 of the world's leaders in this rapidly evolving industry. The New York Stem Cell Summit brings the future of this dynamic industry to life for investors, industry, practitioners and analysts so they can learn about the investment opportunities in the stem cell marketplace, groundbreaking stem cell products that physicians use today and the growing market potential in terms of revenues.

About Cytomedix, Inc.

Cytomedix, Inc. develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma (“PRP”) gel for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma (“PPP”) and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. On February 8, 2012 Cytomedix announced the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell (“ALDHbr”) technology, currently in a Phase 2 trial for the treatment of ischemic stroke. For additional information please visit www.cytomedix.com

Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including many among others, risks and uncertainties related to the Company's ability to successfully integrate this acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and intergrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as “believes,” “forecasted,” “projects,” “is expected,” “remain confident,” “will” and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2010, filed with the SEC and other subsequent filings. These filings are available at http://www.sec.gov.

Read this article:
Cytomedix to Showcase Aldagen's Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings

Baxter Completes Acquisition of Synovis

Regenerative Medicine Comments Off

Feb 152012

DEERFIELD, Ill.–(BUSINESS WIRE)–

Baxter International Inc. (NYSE:BAX – News) announced today that the company has completed its planned acquisition of Synovis Life Technologies, Inc. (NASDAQ: SYNO – News), following approval of the transaction by Synovis shareholders. The acquisition expands Baxter’s regenerative medicine and BioSurgery franchise by adding biological and mechanical products from Synovis used for soft tissue repair and microsurgery in a variety of surgical procedures.

“The acquisition enhances Baxter’s ability to offer a broad range of tools used to repair and reconstruct soft tissue damaged by disease or injury, as well as specific tools used in a variety of microsurgical procedures,” said Ludwig Hantson, president of Baxter’s BioScience business. “We look forward to welcoming the Synovis employees and organization into Baxter as we begin the business integration process.”

Baxter’s technological leadership in the development of biosurgical and regenerative medicine products is grounded in advancing innovation, enhancing surgical techniques and improving patient outcomes. Baxter advanced the field of tissue sealing and hemostasis more than 30 years ago with the development of TISSEEL Fibrin Sealant (sold under the name TISSUCOL in several countries around the world). Today, Baxter is adding the Synovis soft tissue repair and microsurgery products to the company’s existing line of biological products and delivery devices used for hemostasis, tissue sealing, adhesion reduction, and hard tissue regeneration.

Synovis shareholders approved the offer of $28 per share, which equates to $325 million of equity value or approximately $260 million after adjusting for the net cash. Synovis reported annual sales of $82.4 million for the fiscal year ending October 31, 2011.

Synovis develops, manufactures and markets medical devices used primarily in surgical procedures for soft tissue repair, including PERI-STRIPS DRY, TISSUE-GUARD and VERITAS Collagen Matrix. These products are used in a variety of surgical procedures, including obesity surgery; patching the lining of the brain, vessels, and cardiac defects; hernia repair; and vascular surgery. The Synovis portfolio also includes products used in microsurgery, such as the COUPLER, FLOW COUPLER and GEM MICROCLIP. These products are used for joining small diameter vessels during autologous tissue breast reconstruction; sealing small blood vessels; and head, neck and hand procedures. Its newest business area is orthopedic and wound management products, with applications ranging from the repair of rotator cuff and other tendon injuries to advanced wound management. These products are primarily used by reconstructive, orthopedic, sports medicine, podiatric, and vascular surgeons.

About Baxter

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Full prescribing information for TISSEEL can be found at: http://www.baxter.com/downloads/healthcare_professionals/products/Tisseel_PI.pdf

This release includes forward-looking statements concerning the company’s acquisition of Synovis Life Technologies, Inc. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company’s ability to successfully integrate Synovis into its existing operations; demand for and market acceptance of new and existing products; actions of regulatory bodies and other governmental authorities including changes to applicable laws and regulations; product quality or patient safety concerns; the impact of U.S. healthcare reform and global austerity measures; and other risks identified in the company’s most recent filing on Form 10-K and other SEC filings, all of which are available on the company’s website. The company does not undertake to update its forward-looking statements.

Follow this link:
Baxter Completes Acquisition of Synovis

Bioheart Acquires Exclusive Rights to Ageless Regenerative Institute's Adipose Cell Technology

Regenerative Medicine Comments Off

Feb 142012

SUNRISE, Fla., Feb. 14, 2012 (GLOBE NEWSWIRE) — Bioheart, Inc. (BHRT.OB) announced today that it has acquired the worldwide exclusive rights to Ageless Regenerative Institute's adipose (fat) derived therapeutic cell technology for use in the cardiac field.

“The Ageless adipose stem cell technology will allow us to broaden our portfolio of product candidates for cardiac patients,” said Mike Tomas, President and CEO of Bioheart. “We have successfully treated patients in Mexico and now we are ready to expand into the US.”

Adipose tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells. Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or LipiCell(TM) in patients with chronic ischemic cardiomyopathy. Transplantation of LipiCell(TM) will be accomplished through endocardial implantations with the MyoStar(TM) Injection Catheter under the guidance of the NOGA(R) cardiac navigation system by Biosense Webster, Inc. — A Johnson & Johnson Company.

Under the terms of the agreement, Bioheart will have a worldwide exclusive license to all of Ageless technology for use in the heart attack and heart failure markets. The agreement provides for upfront and milestone equity payments to Ageless.

Ageless' President and Chief Executive Officer, Dr. Sharon McQuillan, MD added, “We are excited about this collaboration with Bioheart, a leader in developing cell therapies for cardiovascular disease. Together with Bioheart, we can help to revolutionize cardiovascular medicine and improve the current standard of care for these patients.”

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

For more information on Bioheart, visit www.bioheartinc.com.

About Ageless Regenerative Institute, LLC

The Ageless Regenerative Institute (ARI) is an organization dedicated to the standardization of cell regenerative medicine. The Institute promotes the development of evidence-based standards of excellence in the therapeutic use of adipose-derived stem cells through education, advocacy, and research. ARI has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more. ARI has successfully treated hundreds of patients utilizing these cellular therapies demonstrating both safety and efficacy. For more information about regenerative medicine please visit www.agelessregen.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

AxoGen Names Jill Schiaparelli Senior Vice President of Business Strategy & Marketing

Regenerative Medicine Comments Off

Feb 132012

ALACHUA, Fla.–(BUSINESS WIRE)–

AxoGen, Inc. (OTCBB: AXGN.OB – News), an emerging regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced Jill Schiaparelli will be joining as its Senior Vice President of Business Strategy and Marketing.

“Strong sales growth is key to our continued success,” states Karen Zaderej, Chief Executive Officer of AxoGen, Inc. “Jill’s extensive strategic marketing and leadership experience in the healthcare space will add significant value to the team and will be ideal as we execute our growth initiatives.”

Prior to joining the team, Ms. Schiaparelli was a principal of JS Strategic Partners, a consultancy she founded to provide business strategy, growth initiatives, and commercialization implementation to healthcare companies and service providers. Jill also served as Global Vice President of Commercial Strategy & Business Development for ApaTech – a world leader in orthobiologics acquired by Baxter Healthcare. Earlier in her career, she held several senior positions in strategic marketing, sales operations, and analytics for the Johnson & Johnson family of companies and spent nearly a decade in investment banking.

Ms. Schiaparelli received her MBA from the Stern School of Business at New York University and a Bachelor’s of Science in Business Administration from Boston University.

About AxoGen, Inc.

AxoGen (OTCBB: AXGN.OB – News) is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes Avance® Nerve Graft, which AxoGen believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed). AxoGen’s portfolio also includes AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector that protects nerves during the body’s healing process after surgery. AxoGen is bringing the science of nerve repair to life with thousands of surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

AxoGen (formerly known as LecTec Corporation) is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the rest here:
AxoGen Names Jill Schiaparelli Senior Vice President of Business Strategy & Marketing

cancer and regenerative medicine lecture - Video

Regenerative Medicine Comments Off

Feb 122012

11-02-2012 13:48

Read the original here:
cancer and regenerative medicine lecture – Video

Regenerative Medicine: Current Concepts and Changing Trends - Video

Regenerative Medicine Comments Off

Feb 122012

26-01-2012 07:54 Air date: Wednesday, January 25, 2012, 3:00:00 PM Timedisplayed is Eastern Time, Washington DC Local Category: Wednesday Afternoon Lectures Description: Patients with diseased or injured organs may be treated with transplanted organs. There is a severe shortage of donor organs which is worsening yearly due to the aging population. Regenerative medicine and tissue engineering apply the principles of cell transplantation, material sciences, and bioengineering to construct biological substitutes that may restore and maintain normal function in diseased and injured tissues. Stem cells may offer a potentially limitless source of cells for tissue engineering applications and are opening new options for therapy. Recent advances that have occurred in regenerative medicine will be reviewed and applications of these new technologies that may offer novel therapies for patients with end-stage tissue and organ failure will be described. The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide. For more information, visit: The NIH Director’s Wednesday Afternoon Lecture Series Author: Anthony Atala, MD, Wake Forest School of Medicine Runtime: 00:51:29 Permanent link: videocast.nih.gov

How It's Made Season 17, Episode 1 Decorative Sombreros, Salad Dressings, Cap Guns, Regenerative Medicine - Video

Regenerative Medicine Comments Off

Feb 102012

09-01-2012 16:22

See the original post:
How It’s Made Season 17, Episode 1 Decorative Sombreros, Salad Dressings, Cap Guns, Regenerative Medicine – Video

Harvard Bioscience, Inc. Acquires AHN

Regenerative Medicine Comments Off

Feb 082012

HOLLISTON, Mass. — Harvard Bioscience, Inc. , a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that …

Tengion to Present at the 14th Annual BIO CEO & Investor Conference

Regenerative Medicine Comments Off

Feb 072012

WINSTON-SALEM, N.C., Feb. 7, 2012 /PRNewswire/ – Tengion, Inc. (NASDAQ: TNGN – News), a leader in regenerative medicine, today announced that Brian Davis, Chief Financial Officer and Vice President, Finance …

See more here:
Tengion to Present at the 14th Annual BIO CEO & Investor Conference

Older Entries

FireFox!	Start Your Own Web Hosting Company	Kids Furniture
Web Hosting	Advertise Here $10 a Month	Affordable web-hosting
Pierre Teilhard De Chardin

Vomaris Innovations, Inc. Names New CEO

Makucell™ Announces Key Scientific Presentations and Launch of a Large, Multicenter Use Study of Asymmtate™

Makucell(TM) Announces Key Scientific Presentations and Launch of a Large, Multicenter Use Study of Asymmtate(TM)

Celling Biosciences Sponsors 7th Annual Stem Cell Summit

Regenerative medicine mujaddidon's project.wmv - Video

Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview

BioTime CEO Michael D. West to Present at New York Stem Cell Summit

Histogenics to Present at 7th Annual New York Stem Cell Summit

Biomask: Improving Facial Burn Treatment for Soldiers in the Field

Provia Labs Makes Chicago Midwinter Meeting Debut and Launches Store-A-Tooth™ Dental Stem Cell Preservation, Enabling ...

Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for ...

Cytomedix to Showcase Aldagen's Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings

Baxter Completes Acquisition of Synovis

Bioheart Acquires Exclusive Rights to Ageless Regenerative Institute's Adipose Cell Technology

AxoGen Names Jill Schiaparelli Senior Vice President of Business Strategy & Marketing

cancer and regenerative medicine lecture - Video

Regenerative Medicine: Current Concepts and Changing Trends - Video

How It's Made Season 17, Episode 1 Decorative Sombreros, Salad Dressings, Cap Guns, Regenerative Medicine - Video

Harvard Bioscience, Inc. Acquires AHN

Tengion to Present at the 14th Annual BIO CEO & Investor Conference

Pages

Recommended Sites

Categories

Recent Posts

Subscribe to prometheism-pgroup

Pages

Recommended Sites

Categories

Recent Posts

Tags

Subscribe to prometheism-pgroup